New Targets, New Hope in SMA: A 2020 Congress Coverage

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..

Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC

Visit https://www.peervoice.com/APW860 to view the entire programme with slides. After completing “Michael Heuser, MD -  Case Study Challenge: Managing FLT3-ITD–Positive AML”, participants will be able to: Implement evidence-based best practice approaches to management of newly diagnosed FLT3-ITD–positive acute myeloid leukaemia (AML); Recognise adverse events associated with the use of FLT3 inhibitors and strategies to monitor for and manage these events; and Assess the real-world considerations of utilising measurable residual disease (MRD) as a clinical biomarker in the management of AML.

Michael Heuser, MD -  Case Study Challenge: Managing FLT3-ITD–Positive AML

Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.

Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

Visit https://www.peervoice.com/NYE860 to view the entire programme with slides. After completing “Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy”, participants will be able to: Assess current treatment options for first-line management of advanced urothelial carcinoma (aUC), including maintenance therapy; Identify patients with aUC who may benefit from maintenance therapy; Formulate appropriate maintenance therapy plans for patients with aUC; and Identify emerging therapies, including maintenance therapies, for the management of aUC.

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Visit https://www.peervoice.com/UGT860 to view the entire programme with slides. After completing “Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer ”, participants will be able to: Assess the clinical relevance of randomised controlled trial (RCT) data evaluating the safety and efficacy of TROP2-directed therapies in the management of HR+/HER2- advanced breast cancer; and Identify patients with HR+/HER2- advanced breast cancer who may benefit from treatment with a TROP2-directed therapy.

New Targets, New Hope in SMA: A 2020 Congress Coverage

Download our free app to listen on your phone